Literature DB >> 20807312

Neuronal over-expression of chromogranin A accelerates disease onset in a mouse model of ALS.

Samer Abou Ezzi1, Roxanne Larivière, Makoto Urushitani, Jean-Pierre Julien.   

Abstract

Recent studies provided evidence that chromogranins can interact with mutant superoxide dismutase 1 (SOD1) and that chromogranin B (CgB) may act as a susceptibility gene and modifier of onset in amyotrophic lateral sclerosis (ALS). To further investigate the role of chromogranins in ALS pathogenesis, we generated SOD1(G37R) mice that over-express CgA under the control of Thy1 promoter. Here, we report that neuronal over-expression of CgA in SOD1(G37R) mice caused acceleration of onset of motor impairment and exacerbation of motor neuron degeneration. The use of monoclonal antibody specific to misfolded mutant SOD1 demonstrated a higher level of misfolded SOD1 species in double transgenic mice compared to SOD1(G37R) mice, suggesting a stabilization of pathogenic SOD1 species by excess CgA. These results suggest a role of chromogranins as modulators of disease onset in ALS pathogenesis.
© 2010 The Authors. Journal of Neurochemistry © 2010 International Society for Neurochemistry.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807312     DOI: 10.1111/j.1471-4159.2010.06979.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

Review 1.  Chromogranin peptides in brain diseases.

Authors:  Michael Willis; Irmgard Leitner; Kurt A Jellinger; Josef Marksteiner
Journal:  J Neural Transm (Vienna)       Date:  2011-04-30       Impact factor: 3.575

2.  Enhanced Cortical Metabolic Activity in Females and Males of a Slow Progressing Mouse Model of Amyotrophic Lateral Sclerosis.

Authors:  Dipak Roy; Madhuri Puvvada; Sampath K T Kapanaiah; Anant Bahadur Patel
Journal:  Neurochem Res       Date:  2022-03-26       Impact factor: 3.996

Review 3.  The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Vladimir N Uversky
Journal:  Autophagy       Date:  2017-12-17       Impact factor: 16.016

Review 4.  SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.

Authors:  Peter I Joyce; Pietro Fratta; Elizabeth M C Fisher; Abraham Acevedo-Arozena
Journal:  Mamm Genome       Date:  2011-06-26       Impact factor: 2.957

Review 5.  The microglial-motoneuron dialogue in ALS.

Authors:  S H Appel; W Zhao; D R Beers; J S Henkel
Journal:  Acta Myol       Date:  2011-06

Review 6.  Protein misdirection inside and outside motor neurons in Amyotrophic Lateral Sclerosis (ALS): a possible clue for therapeutic strategies.

Authors:  Akemi Ido; Hidenao Fukuyama; Makoto Urushitani
Journal:  Int J Mol Sci       Date:  2011-10-19       Impact factor: 5.923

7.  Sex-dependent effects of chromogranin B P413L allelic variant as disease modifier in amyotrophic lateral sclerosis.

Authors:  Yasuyuki Ohta; Genevieve Soucy; Daniel Phaneuf; Jean-Nicolas Audet; François Gros-Louis; Guy A Rouleau; Hélène Blasco; Philippe Corcia; Peter M Andersen; Frida Nordin; Toru Yamashita; Koji Abe; Jean-Pierre Julien
Journal:  Hum Mol Genet       Date:  2016-11-01       Impact factor: 6.150

8.  Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: implications for the assessment of putative therapeutic agents.

Authors:  Pierre Zwiegers; Grace Lee; Christopher A Shaw
Journal:  J Negat Results Biomed       Date:  2014-08-08

Review 9.  Salivary biomarkers for the diagnosis and monitoring of neurological diseases.

Authors:  Raymond Farah; Hayat Haraty; Ziad Salame; Youssef Fares; David M Ojcius; Najwane Said Sadier
Journal:  Biomed J       Date:  2018-05-10       Impact factor: 4.910

Review 10.  Small junction, big problems: Neuromuscular junction pathology in mouse models of amyotrophic lateral sclerosis (ALS).

Authors:  Abrar Alhindi; Ines Boehm; Helena Chaytow
Journal:  J Anat       Date:  2021-06-07       Impact factor: 2.921

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.